-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
has -X- _ O
been -X- _ O
responsible -X- _ O
for -X- _ O
numerous -X- _ O
outbreaks -X- _ O
since -X- _ O
the -X- _ O
1970s -X- _ O
, -X- _ O
with -X- _ O
the -X- _ O
most -X- _ O
recent -X- _ O
outbreak -X- _ O
taking -X- _ O
place -X- _ O
between -X- _ O
2014 -X- _ O
and -X- _ O
2016 -X- _ O
and -X- _ O
causing -X- _ O
an -X- _ O
international -X- _ O
public -X- _ O
health -X- _ O
emergency. -X- _ O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
EVD -X- _ I-Patient
) -X- _ I-Patient
has -X- _ O
a -X- _ O
high -X- _ O
mortality -X- _ O
rate -X- _ O
and -X- _ O
no -X- _ O
approved -X- _ O
targeted -X- _ O
treatment -X- _ O
exists -X- _ O
to -X- _ O
date. -X- _ O
A -X- _ O
number -X- _ O
of -X- _ O
established -X- _ B-Intervention
drugs -X- _ I-Intervention
are -X- _ O
being -X- _ O
considered -X- _ O
as -X- _ O
potential -X- _ O
therapeutic -X- _ O
agents -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
EVD. -X- _ O
OBJECTIVE -X- _ O
: -X- _ O
We -X- _ O
aimed -X- _ O
to -X- _ O
identify -X- _ O
potential -X- _ O
drug -X- _ O
repositioning -X- _ O
candidates -X- _ O
and -X- _ O
to -X- _ O
assess -X- _ O
the -X- _ O
scientific -X- _ O
evidence -X- _ O
available -X- _ O
on -X- _ O
their -X- _ O
efficacy. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
conducted -X- _ O
a -X- _ O
systematic -X- _ O
literature -X- _ O
search -X- _ O
in -X- _ O
MEDLINE -X- _ O
, -X- _ O
Embase -X- _ O
, -X- _ O
and -X- _ O
other -X- _ O
relevant -X- _ O
trial -X- _ O
registry -X- _ O
platforms -X- _ O
for -X- _ O
studies -X- _ O
published -X- _ O
between -X- _ O
January -X- _ O
1976 -X- _ O
and -X- _ O
January -X- _ O
2017. -X- _ O
We -X- _ O
included -X- _ O
drug -X- _ O
screening -X- _ O
, -X- _ O
preclinical -X- _ O
studies -X- _ O
, -X- _ O
and -X- _ O
clinical -X- _ O
studies -X- _ O
on -X- _ O
repurposed -X- _ B-Intervention
drugs -X- _ I-Intervention
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
EVD. -X- _ O
The -X- _ O
risk -X- _ O
of -X- _ O
bias -X- _ O
for -X- _ O
animal -X- _ O
studies -X- _ O
and -X- _ O
nonrandomized -X- _ O
clinical -X- _ O
studies -X- _ O
was -X- _ O
assessed. -X- _ O
The -X- _ O
quality -X- _ O
of -X- _ O
reporting -X- _ O
for -X- _ O
case -X- _ O
series -X- _ O
and -X- _ O
case -X- _ O
reports -X- _ O
was -X- _ O
evaluated. -X- _ O
Finally -X- _ O
, -X- _ O
we -X- _ O
selected -X- _ O
drugs -X- _ O
approved -X- _ O
by -X- _ O
established -X- _ O
regulatory -X- _ O
authorities -X- _ O
, -X- _ O
which -X- _ O
have -X- _ O
positive -X- _ O
in -X- _ O
vitro -X- _ O
study -X- _ O
outcomes -X- _ O
and -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
additional -X- _ O
animal -X- _ O
or -X- _ O
clinical -X- _ O
trial. -X- _ O
RESULTS -X- _ O
: -X- _ O
We -X- _ O
identified -X- _ O
3301 -X- _ O
publications -X- _ O
, -X- _ O
of -X- _ O
which -X- _ O
37 -X- _ O
studies -X- _ O
fulfilled -X- _ O
our -X- _ O
inclusion -X- _ O
criteria. -X- _ O
Studies -X- _ O
were -X- _ O
highly -X- _ O
heterogeneous -X- _ O
in -X- _ O
terms -X- _ O
of -X- _ O
study -X- _ O
type -X- _ O
, -X- _ O
methodology -X- _ O
, -X- _ O
and -X- _ O
intervention. -X- _ O
The -X- _ O
risk -X- _ O
of -X- _ O
bias -X- _ O
was -X- _ O
high -X- _ O
for -X- _ O
13 -X- _ O
out -X- _ O
of -X- _ O
14 -X- _ O
animal -X- _ O
studies. -X- _ O
We -X- _ O
selected -X- _ O
11 -X- _ O
drugs -X- _ O
with -X- _ O
potential -X- _ O
anti-EVD -X- _ O
therapeutic -X- _ O
effects -X- _ O
and -X- _ O
summarized -X- _ O
their -X- _ O
evidence. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Several -X- _ B-Outcome
established -X- _ I-Outcome
drugs -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
therapeutic -X- _ I-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
EVD -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
the -X- _ I-Outcome
quality -X- _ I-Outcome
and -X- _ I-Outcome
quantity -X- _ I-Outcome
of -X- _ I-Outcome
current -X- _ I-Outcome
scientific -X- _ I-Outcome
evidence -X- _ I-Outcome
is -X- _ I-Outcome
lacking. -X- _ I-Outcome
This -X- _ O
review -X- _ O
highlights -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
well-designed -X- _ O
and -X- _ O
conducted -X- _ O
preclinical -X- _ O
and -X- _ O
clinical -X- _ O
research -X- _ O
to -X- _ O
establish -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
potential -X- _ O
repurposed -X- _ B-Intervention
drugs -X- _ I-Intervention
against -X- _ O
EVD -X- _ O
. -X- _ O

